Cohance Lifesciences Faces Financial Metric Adjustments Amid Mixed Performance Indicators

Cohance Lifesciences, a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment reflecting changes in its financial metrics. The latest assessment indicates a revision in its score, attributed to a notable shift in financial performance during the quarter ending March 2025.
Key indicators reveal that the company's profit after tax (PAT) for the latest six months stands at Rs 124.89 crore, showcasing a growth rate of 24.74%. However, the quarterly PAT has experienced a decline, reported at Rs 42.01 crore, which marks a significant drop compared to the previous four-quarter average. Additionally, the debtors turnover ratio has reached a low of 4.21 times, while the operating profit to interest ratio is at its lowest, recorded at 12.79 times.

Despite these challenges, Cohance Lifesciences has demonstrated strong market performance over the past year, achieving a return of 67.75%, significantly outpacing the broader market. The stock's current price is Rs 1024.00, with a 52-week high of Rs 1,359.00 and a low of Rs 597.00.

For those interested in further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.